NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostagland...(eement. Several follow-up compounds from...),Health

Date:5/6/2008

eement. Several follow-up compounds from this agreement have generated promising results in a validated in vivo model of abnormally high IOP, compared to a commonly used reference drug. Pfizer's option to obtain an exclusive worldwide license to these compounds currently runs until May 2009 and their successful development and launch would result in milestone payments of euro 102 million and industry standard royalties on sales.

Pfizer is currently conducting a phase 2 study for PF-03187207 in Japan and has indicated that it would consider continuing the development of PF-03187207 for potential registration in Asia, including Japan, depending on the results of this study which are expected in Q3 2008. NicOx and Pfizer are currently in discussions regarding the rest-of-world rights to PF-03187207. Asia currently accounts for 20% of Pfizer's Xalatan(R) sales (source: IMS) (see NOTE).

Michele Garufi, Chairman and Chief Executive Officer of NicOx, commented: "We believe these results for PF-03187207 suggest nitric oxide donation can bring therapeutic benefit through improved intraocular pressure lowering. Although Pfizer has decided that PF-03187207 does not meet its specific requirements for the U.S. and European markets, we believe this phase 2 study demonstrates a clear commercial potential for PF-03187207 and we are exploring possible strategies with Pfizer to unlock this value. Moreover, the promising results from our joint research program make us confident that a follow-up candidate will be selected by Pfizer with the potential for further improvement over existing treatments."

Results of the U.S. phase 2 study

The phase 2 dose-finding study for PF-03187207 was initiated in the United States in March 2007 and was designed to compare the safety and efficacy of several doses of PF-03187207 to the marketed dose of Xalatan(R) 0.005%. The randomized, double-masked study enrolled 215 patients with primary open-angle glaucoma or ocular hypert
'/>"/>

SOURCE NicOx S.A. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories